News Archive Navigation
Showing 48 results
Media ReleaseNovartis Singapore Partners Breast Cancer Foundation to Support the Community Mammobus ProgrammeMonday, 23 October 2023 — Breast cancer continues to be one of the most common cancers among women in Singapore, accounting for 17.2% of all cancer deaths among females. This concerning statistic is…
Media ReleaseNovartis receives approval in Singapore for LEQVIO® (inclisiran), an innovative medication that changes the treatment paradigm for patients with high cholesterolLeqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.1, 2 Cardiovascular disease (CVD) is…
Remote Patient Monitoring: The Unstoppable Wave of New Care Models – The Records
In The NewsSingapore approves an innovative medication for patients with high cholesterolLeqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.
In The NewsCell therapy for relapsed cancer patientsSingapore has successfully treated its first patient using what is known as chimeric antigen receptor T-cell, or CAR-T therapy.
In The NewsFactories: Making the FutureEver wondered what it's like inside some of Singapore's factories? This special feature documentary looks at cutting-edge products designed and manufactured in the city-state that will impact the way…
In The NewsMultinational pharmaceutical companies partner with local businesses to help economic recovery
Media ReleaseNovartis receives approval for Kymriah® (tisagenlecleucel) by Health Sciences Authority as Singapore’s first commercially approved CAR-T therapyKymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved in Singapore, is indicated as a one-time treatment manufactured individually for each patient. Novartis works closely…